ASCO in January. You better start adding now if you want shares.
"Melanoma and pancreatic cancer indications put Abraxane on $1B trajectory. Our FY12 revenue estimate for Abraxane is currently $460M. We estimate the revenue potential from melanoma is in the $200-250M range while pancreatic cancer could add another $500M-1B depending on the magnitude of the clinical benefit. CELG presented positive data from a pivotal Phase 3 trial for Abraxane in melanoma cancer earlier this week at the Society for Melanoma Research annual meeting. In January 2013, CELG will present the results of their Phase 3 registration study for Abraxane in pancreatic cancer at the ASCO GI Symposium".